Animal models of human cytomegalovirus (CMV) infections have not been available to study pathogenesis or to evaluate antiviral drugs. Severe combined Immunodeficdent mice implanted with human fetal tissues (SCID-hu) were found to support CMV replication and may provide a model for this species-specific virus. When conjoint implants of human fetal thymus and liver were inoculated with a low-passagenumber isolate of CMV, strain Toledo, consistent high-level viral replication was detected 5, 12, 15, 28, and 35 days after inoculation and virus replication continued for up to 9 months. Other human tissue implants, including hug and colon, were also found to support viral growth but with greater variability in levels and for a shorter duration. As expected, the species specificity of human CMV was preserved in this model such that virus was detected in the human conjoint thymus/liver implant but not i surrounding mouse tissues. The majority of virus-infected cells were laled in the thymic medulla rather than cortical region of the implant and imm u ne analysis identified epithelial cells rather than any hematopoletic cell population as the principal hosts for viral replication. Finally, treatment of infected animals with ganciclovir reduced viral replication, thereby demonstrating the value of this system for evaluating antiviral therapies. This animal model opens the way for a range of investigations not previously possible with human CMV.
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Human cytomegalovirus (CMV), a ubiquitous human virus, is as an important pathogen of immunocompromised individuals and neonates (1, 2) . Disease in immunocompromised individuals follows either from primary infection or from reactivation of latent infection. Due to the strict species specificity of this virus and to the absence of any animal model that employs human CMV, it has been difficult to systematically investigate viral pathogenesis, tissue tropism, or latency or to undertake preclinical evaluation of antiviral drugs. Instead, investigators have relied upon murine CMV and other nonhuman animal viruses as models of infection or have developed cell culture models to mimic viral persistence, latency, or tissue tropism.
The persistence of CMV after primary infection is associated with a leukocyte population and it has long been known that virus may be transmitted with blood. Monocytes have been implicated as sites of viral persistence in the normal seropositive adult (3) (4) (5) ; however, other blood cell types, including T cells and various bone marrow cell types (6) (7) (8) , may also be involved. Epithelial cells have long been recognized as targets for the growth and dissemination of CMV (2, 9, 10) , particularly in immunocompromised individuals. In the normal healthy individual, epithelial cells in the ducts of the salivary glands and renal tubules are the predominant cell population supporting persistent viral production. Thus, tTo whom reprint requests should be addressed.
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inspected (usually >3 mm3) just prior to inoculation. Lung tissue implants were made under the kidney capsule, intestine was implanted subcutaneously, and skin was introduced as full-thickness dermal grafts. All fetal tissue samples were screened for human immunodeficiency virus (17) . All surgical procedures were carried out under anesthesia [5% (wt/vol) ketamine/2.5% (wt/vol) xylazine in phosphate-buffered saline (PBS)] and approved by animal use committees at SyStemix and Stanford University.
Virus Inoculation and Titration. One to 6 months after implant, SCID-hu mice were anesthetized and implants under the kidney capsule were exposed with an 8-mm incision over the left costovertebral angle. A titered frozen virus stock was quickly thawed and =0.02 ml was inoculated under the surface of the exposed implant using a 30-gauge needle. Animals were observed daily for abnormal behavior or illness. At various times after inoculation, animals were sacrificed by cervical dislocation and the implants were removed, minced, placed into 2 ml of milk/medium, and sonicated. Virus titers were determined by plaque assay on monolayers of HFFs with a limit of detection of 10 plaqueforming units (pfu) per ml of the sonicate.
In Situ Detection of I8-Galactosidase and Antigens. A portion of the implants was immersed in PBS with 4% (wt/vol) paraformaldehyde at 40C followed by PBS with 10%6 (wt/vol) sucrose and then 20% sucrose and embedded in OTC compound (Miles) in an acetone/dry ice bath. Frozen sections (10 Am) were collected on glass slides and fixed with hematoxylin and/or 5-bromo-4-chloro-3-indolyl P-D-galactoside (150 ,ug/ml) as described (21) . Frozen sections (6 ,um) for immunofluorescence analysis were made from tissues embedded in OTC compound without prior fixation and were subsequently air-dried and fixed with acetone for 1 min at room temperature. For double-label fluorescence analysis, tissue sections were incubated with murine monoclonal antibodies (mAbs) directed against human keratin (AE1 and AE3, Boehringer Mannheim) at a 1:50 dilution, followed with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Caltag, South San Francisco, CA) at a 1:100 dilution. Tissue sections were extensively washed in PBS, exposed to normal mouse serum, and then incubated with mAb to CMV nuclear antigen ICP36 (DAKO-CMV, Dakopatts, Glostrup, Denmark) at a 1:50 dilution. After extensive washing with PBS, a second-stage Texas red-conjugated goat anti-mouse IgG (Caltag) was used at a 1:100 dilution. Under these conditions the keratin-positive cells appeared yellow when photographed as double exposures first under FITC and then under rhodamine filters. FITC-conjugated anti-human CD45 mAb (HLE, Becton Dickinson), FITC-conjugated anti-human CD15 mAb (LeuM1, Becton Dickinson), and phycoerythrinconjugated anti-human CD1 mAb (T6, Coulter) were used at 1:50 dilutions. Photomicrographs were taken using an epifluorescent microscope (Nikon).
Ganciclovir Treatment. Ganciclovir (from Julian Verheyden, Syntex) was dissolved in sterile water at 1.5 mg/ml. Animals received ganciclovir at 1.5, 0.5, or 0.125 mg/ml in drinking water from 6 h until 12 days after inoculation. For parenteral treatment, mice were injected interperitoneally (i.p.) with ganciclovir at 8 or 40 mg per kg per day, starting 4 h after inoculation and continuing daily for 12-13 days.
RESULTS
CMV Replicates in the SCID-hu Mouse. The initial aim of these studies was to determine whether human CMV was capable of replicating in human fetal tissue implants. We investigated the time course of viral replication in human Thy/Liv implants carried by SCID-hu mice after an inoculum of 4 x 105 pfu of the low-passage Toledo strain of CMV was injected directly into the exposed implant. As expected 35 days after inoculation. The reasons for such variability may include poor inoculation or some other variation between implants. Significantly less variability was observed in later experiments as the manipulations became more routine.
To determine the influence of the input dose on the levels of replication, we inoculated groups of animals with 4 x 105 pfu, 4 x 104 pfu, or 4 x 103 pfu of virus. All three inocula resulted in readily detectable growth 12 days after inoculation, and titers decreased in parallel with the dilution of the input virus (Fig. 2) . These results established a doseresponse relationship and showed the susceptibility of Thy/ Liv SCID-hu mice to as little as 4000 pfu of CMV (in 0.02 ml). This level of sensitivity should facilitate the investigation of growth properties of freshly isolated strains that grow poorly in cultured cells.
CMV replication was restricted to the implant and was not detected at any time in peripheral blood leukocytes where a small population may be derived from the Thy/Liv implant (11, 22) (data not shown). Consistent with the wellestablished species specificity of this virus (23) , Thy/Liv implants were found to be virus-positive, but the surrounding mouse kidney taken from four animals was found to be free of virus (data not shown). It should be noted that uninoculated human fetal tissues failed to yield CMV when assayed, We further investigated the ability of human CMV to replicate in other implanted human tissue types. After direct inoculation of CMV into implants of human fetal lung or colon, growth was observed although not as consistently or at the same high levels as observed in the Thy/Liv implant. Similarly, subcutaneous inoculation of implanted human skin resulted in low and variable levels of viral replication. In all of these instances, virus was only sporadically detected beyond a peak 5-9 days after inoculation (data not shown).
CMV Replicates in Epithelial Ceils in Thy/Liv Implants. Precise localization of productively infected target cells was carried out by histological observation and immunohistochemical staining of infected tissue sections 7-14 days after inoculation. Half of each implant was processed for titration of virus and the remainder was processed to make frozen sections. Cytopathic effects were more readily observed at later times after inoculation (12-14 days) . Initial histological observation of hematoxylin-stained sections 14 days after inoculation revealed minimal CMV cytopathic effects; only occasional cells with an "owl-eye" appearance were observed (Fig. 3A) .
To (Fig. 3B) . At this time, infected cells were rarely clustered. The virus-infected cells appeared to be localized in thymic medulla, in an area rich in Hassall's bodies, rather than in cortical areas of the implant.
To identify the cell type(s) infected by CMV in the implants, immunofluorescence with a mAb directed at viral nuclear antigen was used to colocalize virus and various cellular markers. Animals were sacrificed and implants were examined for presence of viral antigens 9-14 days after inoculation with 4 x 105 pfu ofthe Toledo strain. The majority of cells that were found to express viral antigens appeared to be epithelial cells in the thymic medulla as best demonstrated by a double-label indirect immunofluorescence procedure using murine mAbs directed at a CMV nuclear antigen (Fig.  4A ) and human keratins, as markers for epithelial cells (Fig.  4B) . When viewed under separate FITC or rhodamine/Texas red filters, CMV antigen and keratin colocalized in the same cells. When photographed using a double exposure, cells with both antigens appeared to have yellow cytoplasmic fluorescence and red nuclear fluorescence (Fig. 4C) . We further evaluated tissue sections by using mAbs directed at other cell populations. CMV-antigen-positive cells were negative for CD45 (the common leukocyte antigen found on thymocytes and monocytes), CD1 (a marker of thymocytes and thymic dendritic cells), and CD15 (a myelomonocytic cell marker). These results indicated that the CMV replication occurred in epithelial cells localizing to the region analogous to the thymic medulla.
Inhibition of CMV Growth by Gancilovir. A preliminary experiment sought to evaluate the ability of ganciclovir to inhibit viral replication in Thy/Liv implants when added to the drinking water starting 6 h after inoculation. We found a dose-dependent reduction in titers 12 days after inoculation (Fig. 5A ), similar to oral doses effective against murine CMV (24) , with no obvious negative side effects of the drug. Parenterally administered ganciclovir (8 or 40 mg per kg per day) starting 4 h after inoculation reduced titers from two to four orders of magnitude (Fig. 5B) , an effect remarkably similar to the prophylactic and therapeutic regimens currently in use on humans (25) . These data predict that SCID-hu mice will aid in the evaluation of the antiviral activity of other drugs and biologics. We initially chose to use the Toledo strain of CMV because of its low-passage history, high-titered growth, and demonstrated virulence characteristics (19) . Many ofthe parameters of the infection indicated a level of specificity not obvious from cell-culture studies on CMV. (i) The Toledo strain exhibited persistent growth that did not diminish over several weeks of observation. (ii) Consistently higher titer growth was exhibited by Toledo as compared to laboratory-passaged strains of CMV (unpublished observations). These characteristics may be related to substantially increased virulence exhibited by the Toledo strain relative to the Towne strain of CMV (19) . These growth and virulence differences predict the existence of viral gene functions that may be missing from the laboratory strains. These determinants may be identified and mapped using the SCID-hu mouse model.
Although virus continued to be produced in Thy/Liv implants for long periods of time, viral replication was not as widespread as might have been expected based on the fetal origin of the tissues and the lack of any specific immune response to the virus in SCID mice. The few cells that were infected were distributed in the region ofthe implant believed to carry out functions analogous to the medulla of the mature thymus and thus to control the maturation of T cells (22, 27) and did not extend into the cortex. This pattern of infection suggested that epithelial cells in the cortex did not provide the requirements for productive CMV replication. Within the medulla, cell-to-cell spread of virus appeared to proceed slowly even in the absence of an immune response. The pattern of spread, level of replication, and cell-type specificity of CMV infection may be dependent on the virus strain, passage history, or other characteristics.
The most prominent cell type infected by CMV in the Thy/Liv implant was a thymic medullary epithelial cell. The developmental origin of epithelial cells in the thymic medulla is the pharyngeal pouch endoderm, which also gives rise to submandibular epithelial cells (28 
